Jason C Myers

US Patent:

7868014, Jan 11, 2011

Filed:

Oct 13, 2005

Appl. No.:

11/576960

Inventors:

Thomas Charles Britton - Carmel IN, US
Veronique Dehlinger - Basingstoke, GB
Colin Peter Dell - Basingstoke, GB
Bruce Anthony Dressman - Indianapolis IN, US
Jason Kenneth Myers - Indianapolis IN, US
Eric Samuel Nisenbaum - Carmel IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D 401/04
C07D 409/04
A61K 31/506

US Classification:

514275, 514342, 514343, 514370, 514422, 514426, 544330, 5462711, 5462791, 548198, 548527, 548557

Abstract:

The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.

US Patent:

8030304, Oct 4, 2011

Filed:

Sep 17, 2007

Appl. No.:

12/377733

Inventors:

Zhaogen Chen - Indianapolis IN, US
Chafiq Hamdouchi Hamdouchi - Carmel IN, US
Erik James Hembre - Indianapolis IN, US
Philip Arthur Hipskind - New Palestine IN, US
Jason Kenneth Myers - Indianapolis IN, US
Takako Takakuwa - Indianapolis IN, US
James Lee Toth - Knightstown IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A01N 43/58
A01N 43/54
A01N 43/64
A01N 43/78
A01N 43/56
A61K 31/50
A61K 31/505
A61K 31/41
A61K 31/425
A61K 31/415
C07D 239/42
C07D 401/04
C07D 471/04
C07D 471/22
C07D 487/04

US Classification:

514247, 514256, 514257, 514267, 514359, 514365, 514366, 514403

Abstract:

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.

US Patent:

20040157878, Aug 12, 2004

Filed:

Dec 5, 2003

Appl. No.:

10/729529

Inventors:

Bruce Rogers - Mystic CT, US
David Piotrowski - Groton Long Point CT, US
Vincent Groppi - Kalamazoo MI, US
Eric Jacobsen - Chesterfield MO, US
Jason Myers - Indianapolis IN, US
Daniel Walker - Noank CT, US
Donn Wishka - Groton Long Point CT, US
Marc Skaddan - Richland MI, US

International Classification:

C07D471/02
A61K031/4745
A61K031/46

US Classification:

514/303000, 514/304000, 514/305000, 514/412000, 546/118000, 546/125000, 546/135000

Abstract:

Radiolabeled ligands useful as probes for determining the relative abundance, receptor occupancy, and/or function of nicotinic acetylcholine receptors. The compounds of Formula I as described herein are labeled with a radioactive isotopic moiety such as C, F, Br, I or I. Disorders are diagnosed by administering to a mammal a detectably labeled compound and detecting the binding of that compound to the nAChR. The compounds that have been administered are detected using methods including, but not limited to, position emission topography and single-photon emission computed tomography. The present invention is useful in diagnosing a wide variety of diseases and disorders as discussed herein.

US Patent:

20050107425, May 19, 2005

Filed:

Oct 12, 2004

Appl. No.:

10/963922

Inventors:

Bruce Rogers - Mystic CT, US
David Piotrowski - Waterford CT, US
Vicent Groppi - Kalamazoo MI, US
Eric Jacobsen - Chesterfield MO, US
Jason Myers - Indianapolis IN, US
Daniel Walker - Mystic CT, US
Donn Wishka - Mystic CT, US

International Classification:

A61K031/4745
A61K031/46
A61K031/407
A61K031/137
A61K031/445

US Classification:

514304000, 514305000, 514412000, 514317000, 514649000

Abstract:

The present invention relates to compositions and methods to treat ADHD with an α7 nAChR full agonist and psychostimulants and/or monoamine reuptake inhibitors.

US Patent:

20080132551, Jun 5, 2008

Filed:

Mar 24, 2004

Appl. No.:

10/808125

Inventors:

Bruce Nelsen Rogers - Mystic CT, US
David Walter Piotrowski - Waterford CT, US
Brandon J. Margolis - Indianapolis IN, US
Jason K. Myers - Indianapolis IN, US
Vincent Edward Groppi - Kalamazoo MI, US
Daniel G. Rudmann - Fishers IN, US

International Classification:

A61K 31/4439
C07D 417/02
C07D 413/02
A61K 31/422
A61P 25/28
A61P 25/00
A61K 31/427
A61K 31/433
C07D 285/12

US Classification:

514342, 5462721, 514340, 5462687, 548146, 514365, 514363, 548136, 514374, 548215

Abstract:

The invention provides compounds of Formula I:wherein A, B, and X are described herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which α7 nAChR is known to be involved.

US Patent:

20170044138, Feb 16, 2017

Filed:

Aug 5, 2016

Appl. No.:

15/229249

Inventors:

- Indianapolis IN, US
Kevin Charles Fortner - Indianapolis IN, US
Steven Marc Massey - Indianapolis IN, US
Jason Kenneth Myers - Indianapolis IN, US
Antonio Navarro - Indianapolis IN, US
Miles Goodman Siegel - Indianapolis IN, US
Russell Dean Stucky - Indianapolis IN, US

International Classification:

C07D 401/14
C07C 309/04
C07D 401/12

Abstract:

The present invention provides a compound of Formula II:or a pharmaceutically acceptable salt thereof.

US Patent:

20170044163, Feb 16, 2017

Filed:

Aug 5, 2016

Appl. No.:

15/229229

Inventors:

- Indianapolis IN, US
Kevin Charles Fortner - Indianapolis IN, US
Richard Duane Johnston - Greenfield IN, US
Steven Marc Massey - Indianapolis IN, US
Jason Kenneth Myers - Indianapolis IN, US
Qing Shi - Carmel IN, US
Miles Goodman Siegel - Indianapolis IN, US

International Classification:

C07D 487/04
C07C 31/04
C07D 471/04

Abstract:

The present invention provides a compound of Formula II:or a pharmaceutically acceptable salt thereof.